EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY-NC 4.0

Fruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric cancer (GC) or gastro-oesophageal junction adenocarcinoma (GEJ): a multicentre, phase II, single-arm, open-label clinical trial (FRUTINEOGA) protocol

Liucheng Wu iD, Haiqing Yan, Yuzhou Qin, Mingwei Huang, Tingan Wang, Qinwen Jin, Weiyuan Wei

BMJ Open · 2024

DOI: 10.1136/bmjopen-2023-075696 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift BMJ Open, 2024. Verfasst von Liucheng Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Adenocarcinoma, Benzofurans, Esophageal Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, National Natural Science Foundation of GuangXi, Hutchmed (China) Limited.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction Curing locally advanced gastric cancer (GC) or gastro-oesophageal junction adenocarcinoma (GEJ) with surgery alone is challenging. Neoadjuvant chemotherapy (NCT) has become the standard treatment for patients with locally advanced GC/GEJ, and SOX is the most common neoadjuvant regimen in China. The generally good tolerability in patients and fruquintinib’s low potential for drug–drug interaction suggest that it may be highly suitable for combinations with other antineoplastic therapies. A combination of fruquintinib, S-1 and oxaliplatin can be a promising neoadjuvant treatment for locally advanced GC/GEJ. In this phase II study, we aim to investigate the efficacy and toxicity of fruquintinib plus SOX as neoadjuvant treatment for locally advanced GC/GEJ. Methods and analysis The FRUTINEOGA trial is a prospective, multicentre, phase II, single-arm, open-label clinical trial that will enrol 54 patients. Eligible patients will be registered, enrolled and receive 2–4 cycles of fruquintinib plus SOX, after which surgery will be performed and tumour regression will be evaluated. The primary endpoint is the pathological remission rate, and the secondary endpoints are disease-free survival, overall survival, objective response rate, major pathological response rate and R0 resection rate. Ethics and dissemination Written informed consent will be required from all patients enrolled, and it will be provided by them. The study protocol received approval from the independent ethical review committee of Guangxi Medical University Cancer Hospital, Wuming Hospital of Guangxi Medical University and Wuzhou Red Cross Hospital, Wuzhou Gongren Hospital (approval number: CS2021(96)). We will submit the finalised paper for publication on completing the analyses. This study will provide valuable insights to clinicians regarding the safety and efficacy of incorporating fruquintinib into SOX as neoadjuvant treatment for locally advanced GC/GEJ. The findings have the potential to inform future research proposals and may guide the use of fruquintinib in the neoadjuvant setting for locally advanced GC/GEJ. Trial registration number NCT05122091 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsAdenocarcinomaBenzofuransEsophageal NeoplasmsQuinazolinesHumansOxaliplatinNeoadjuvant TherapyProspective StudiesChinaEsophagogastric JunctionAntineoplastic Combined Chemotherapy ProtocolsClinical Trials, Phase II as TopicMulticenter Studies as Topic

Stichwörter der Autor:innen

CHEMOTHERAPYGastrointestinal tumoursSURGERY

Substanzen

OxaliplatinHMPL-013BenzofuransQuinazolines

Autor:innen und Institutionen

  • Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
  • Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China qyz402@126.com.

ORCID-Profile: Liucheng Wu

Förderung

  • National Natural Science Foundation of China
  • National Natural Science Foundation of GuangXi
  • Hutchmed (China) Limited

Zitieren

APA

Wu, L., Yan, H., Qin, Y., Huang, M., Wang, T., Jin, Q., & Wei, W. (2024). Fruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric cancer (GC) or gastro-oesophageal junction adenocarcinoma (GEJ): a multicentre, phase II, single-arm, open-label clinical trial (FRUTINEOGA) protocol. BMJ Open. https://doi.org/10.1136/bmjopen-2023-075696

Vancouver

Wu L, Yan H, Qin Y, Huang M, Wang T, Jin Q, et al. Fruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric cancer (GC) or gastro-oesophageal junction adenocarcinoma (GEJ): a multicentre, phase II, single-arm, open-label clinical trial (FRUTINEOGA) protocol. BMJ Open. 2024. doi:10.1136/bmjopen-2023-075696

BibTeX
@article{Wu2024,
  author = {Wu, Liucheng and Yan, Haiqing and Qin, Yuzhou and Huang, Mingwei and Wang, Tingan and Jin, Qinwen and Wei, Weiyuan},
  title = {Fruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric cancer (GC) or gastro-oesophageal junction adenocarcinoma (GEJ): a multicentre, phase II, single-arm, open-label clinical trial (FRUTINEOGA) protocol},
  journal = {BMJ Open},
  year = {2024},
  doi = {10.1136/bmjopen-2023-075696}
}
Kostenlos starten →